Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-112 Monotherapy in Advanced Solid Tumors and HCC
NCT03439761Phase 2Unknown
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Imifoplatin in solid tumor, hepatocellular carcinoma (HCC), gastric cancer (GC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Status: unknown.
02
Drugs
Imifoplatin
03
Conditions
solid tumorhepatocellular carcinoma (HCC)gastric cancer (GC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03439761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439761.